简介:Objective:Chroniclymphocyticleukemia(CLL)andmantlecelllymphoma(MCL)cellsover-expressaguanineexchangefactor(GEF),Rasgrf-1.ThisGEFincreasesactiveRasasitcatalyzestheremovalofGDPfromRassothatGTPcanbindandactivateRas.ThisstudyaimstostudythemechanismofactionofRasgrf-1inB-cellmalignancies.Methods:N-terminustruncatedRasgrf-1variantshaveahigherGEFactivityascomparedtothefull-lengthtranscriptthereforeaMCLcelllinewithstableover-expressionoftruncatedRasgrf-1wasestablished.TheB-cellreceptor(BCR)andchemokinesignalingpathwayswerecomparedintheRasgrf-1over-expressingandacontroltransfectedcellline.Results:Cellsover-expressingtruncatedformofRasgrf-1haveahigherproliferativerateascomparedtocontroltransfectedcells.BCRwasactivatedbylowerconcentrationsofanti-IgMantibodyinRasgrf-1over-expressingcellsascomparedtocontrolcellsindicatingthatthesecellsaremoresensitivetoBCRsignaling.BCRsignalingalsophosphorylatesRasgrf-1thatfurtherincreasesitsGEFfunctionandamplifiesBCRsignaling.ThisactivationofRasgrf-1inover-expressingcellsresultedinahigherexpressionofphospho-ERK,AKT,BTKandPKC-alphaascomparedtocontrolcells.BesidesBCR,Rasgrf-1over-expressingcellswerealsomoresensitivetomicroenvironmentstimuliasdeterminedbyresistancetoapoptosis,chemotaxisandERKpathwayactivation.Conclusions:ThisGEFproteinsensitizesB-cellstoBCRandchemokinemediatedsignalingandalsoupregulatesanumberofothersignalingpathwayswhichpromotesgrowthandsurvivalofthesecells.
简介:目的:探讨125↑I粒子植入治疗复发性恶性肿瘤的疗效及安全性。方法:31例复发性恶性肿瘤患者,男22例,女9例,年龄19岁-76岁,平均51岁,其中脑胶质瘤1例,鼻咽癌4例,鼻窦癌2例,口咽癌2例,食道癌3例,肺癌5例,乳腺癌1例,肝癌4例,直肠癌3例,宫颈癌1例,骨肉瘤3例,纤维肉瘤2例,31例共36个病灶。在CT或B超引导下将125I粒子植入肿瘤病灶内,采用放射性粒子治疗计划系统(TPS)设计布源,将放射性活度为23.31MBq-29.97MBq的125I粒子按10mm层间距植入。结果:31例36个病灶,完全缓解(CR)8个,部分缓解18个,总有效率72.2%。术中11例出现少量渗血;术后出现胸背痛1例,1例出现少量气胸(肺压缩小于30%),保守治疗后恢复;食道气道瘘1例。结论:125I粒子植入作为常规放化疗治疗复发性恶性肿瘤的一种补充治疗手段,局部控制率高,创伤小,安全性好。
简介:Objective:Toanalyzetheclinicopathologiccharacteristicsandprognosticfactorsofsmallgastrointestinalstromaltumor(GIST)ofthestomach.Methods:Atotalof31smallgastricGISTpatients,including10malesand21females,withamedianageof58years(37-81years),whounderwentsurgeryatanytimefrom1999to2012wereincludedinthisstudy.Theclinicalrecordsofthepatientswereanalyzedretrospectively.Results:Abdominaldiscomfortandpain(10cases,32.3%,respectively)werethetwomostcommoncomplaintsamongthepatients.Allpatientsreceivedsurgery,11receivedgastricwedgeresection,11receivedsubtotalgastrectomy,5receivedlaparoscopicgastricwedgeresection,and4receivedendoscopicsubmucosaldissection.Nosevereadversecomplicationwasobserved.Atotalof29patients(93.5%)werefollowedup.Duringthefollow-up,2patientswerefoundtoexhibittumorrecurrence,and1patienthadlivermetastases.Onepatientdiedoftumorprogression,whileanotherdiedofanothermalignanttumor.Medianprogressionfreesurvival(PFS)timewas120.3months,andmedianoverallsurvival(OS)timewas130.4months.Conclusion:SmallgastricGISThasbetterprognosis.Surgeryisthebestchoicefortherapy.Micro-invasiveproceduresaresafeandeffectiveforelectivepatients.Tumornecrosis,tumorbleeding,andmuscleinvasionarepotentialprognosticfactorsofsmallgastricGIST.
简介:ThechronicinfectionofhepatitisBvirus(HBV)iscloselyrelatedtotheoccurrenceanddevelopmentofhepatocellularcarcinoma(HCC).AccumulatedevidencehasshownthatHBVXprotein(HBxprotein)isamultifunctionalregulatorwithacrucialroleinhepatocarcinogenesis.However,informationonthemechanismbywhichHBVinducesHCCislacking.ThisreviewfocusesonthepathologicalfunctionsofHBxinHBV-inducedhepatocarcinogenesis.Asatransactivator,HBxcanmodulatenuclearfactorkappa-light-chain-enhancerofactivatedBcells(NF-κB)andtranscriptionfactorAP-2.Moreover,HBxcanaffectregulatorynon-codingRNAs(ncRNAs)includingmicroRNAsandlongncRNAs(lncRNAs),suchasmiRNA-205andhighlyupregulatedinlivercancer(HULC),respectively.HBxisalsoinvolvedinepigeneticmodification,includingmethylationandacetylation.HBxinteractswithvarioussignal-transductionpathways,suchasproteinkinaseB/Akt,Wnt/β-catenin,signaltransducerandactivatoroftranscription,andNF-κBpathways.Moreover,HBxaffectscellularfatebyshiftingthebalancetowardcellsurvival.HBxmayleadtothelossofapoptoticfunctionsordirectlycontributestooncogenesisbyachievingtransformingfunctions,whichinducehepatocarcinogenesis.Additionally,HBxcanmodulateapoptosisandimmuneresponsebydirectorindirectinteractionwithhostfactors.WeconcludethatHBxhastensthedevelopmentofhepatoma.
简介:DuckhepatitisBvims(DHBV)DNAwasdetectedindifferenttumorousnodulesofduckswithhepaticmulticentriccancerorintrahepaticmetastasisbySouthernblottechnique.Among7duckswithhepatocellularcarcinomaofmultipletumornodules,thehybridizationpatternofIntegratedDHBVDNAIndifferenttumorousnoduleswasidenticalin3casesanddifferentin2cases.OnecaseshowedasimilarhybridizationpatternintwotumorousnodulesandotheronewasnegativetorDHBVDNA.IntegratedDHBVDNAwasalsoidentifiedinametastaticlungcancerofduckswithhepatocellularcarcinoma.Thehybridizationpatternofmetastasisoflungswasasthesomeasthatinprimaryhepatocellularcarcinoma.ThesamediscretehybridizationbandsInthedifferenttumorousnodulesindicatethatthesenodulesmightarisefromonetransformedcell.ThedifferenthybridizationpatternsInvarioustumorousnodulesshowthatthesetumorousnodulesmightarisefromvarioustransformedcells.Theresultssuggestthatthehyb
简介:Objective:ToassesstheeffectofantiviraltherapyforhepatitisBvirus(HBV)-relatedhepatocellularcarcinoma(HCC)afterradicalhepatectomy.Methods:Atotalof478HBV-relatedHCCpatientstreatedbyradicalhepatectomywereretrospectivelycollected.Patientsinthetreatmentgroup(n=141)receivedpostoperativelamivudinetreatment(100mg/d),whereaspatientsinthecontrolgroup(n=337)didnot.Recurrence-freesurvival(RFS)rates,overallsurvival(OS)rates,treatmentsforrecurrentHCCandcauseofdeathwerecomparedbetweenthetwogroups.Propensityscorematching(PSM)analysiswasalsoconductedtoreduceconfoundingbiasbetweenthetwogroups.Results:The1-,3-,and5-yearRFSratesdidn’tsignificantlydifferbetweenthetwogroups(P=0.778);however,the1-,3-,and5-yearOSratesinthetreatmentgroupweresignificantlyhigherthanthoseinthecontrolgroup(P=0.002).Similarresultswereobservedinthematcheddata.SubgroupanalysisshowedthatantiviraltreatmentconferredasignificantsurvivalbenefitforBarcelonaClinicalLiverCancerstageA/Bpatients.FollowingHCCrecurrence,morepeopleinthetreatmentgroupwereabletochoosecurativetreatmentsthanthoseinthecontrolgroup(P=0.031).Forcauseofdeath,fewerpeopleinthetreatmentgroupdiedofliverfailurethanthoseinthecontrolgroup(P=0.041).Conclusion:PostoperativeantiviraltherapyincreaseschancesofreceivingcurativetreatmentsforrecurrentHCCandpreventsdeathbecauseofliverfailure,therebysignificantlyprolongingOS,especiallyinearly-orintermedian-stagetumors.
简介:许多人类疾病的发生和发展可归因于一些基因的异常表达,从而导致疾病的发生。其中一部分基因是在核因子kappaB(nuclearfactor-kappaB,NF—κB)调控下进行的。NF—κ是广泛存在于哺乳动物中的转录因子,是由Sen等于1986年首先在B细胞中发现的一种核蛋白。因它能与B细胞免疫球蛋白上的K轻链基因增强子κB序列(GGGACTITCC)特异结合而得名。实际上它能与多种细胞基因的启动子和增强子序列位点发生特异性结合,并促进转录和表达,参与众多与免疫和炎症反应有关的基因转录的调控。它的异常激活或完全抑制与多种疾病的发生有关。在控制细胞增殖、凋亡、肿瘤的发生、发展和耐药问题上均起着重要的作用。因此深入探讨NF—κB在体内病理状态下的活化机制以及其与细胞、基因之间的调节作用具有重要的意义。现就NF—κB的组成、结构、激活途径以及与肿瘤的关系作一综述。
简介:Objective:Cancercellradioresistanceisastumblingblockinradiationtherapy.TheactivityinthenuclearfactorkappaB(NFκB)pathwaycorrelateswithanti-apoptoticmechanismsandincreasedradioresistance.TheIKKcomplexplaysamajorroleinNFκBactivationuponnumeroussignals.Inthisstudy,weexaminedtheinteractionbetweenionizingradiation(IR)anddifferentmembersoftheIKK-NFκBpathway,aswellasupstreamactivators,RAF1,ERK,andAKT1.Methods:Theeffectof4GyofIRontheexpressionoftheRAF1-ERK-IKK-NFκBpathwaywasexaminedinA549andH1299lungcancercelllinesusingWesternblotanalysisandconfocalmicroscopy.WeexaminedchangesinradiationsensitivityusinggenesilencingorpharmacologicalinhibitorsofERKandIKKβ.Results:IKKα,IKKγ,andIκBαincreaseduponexposuretoIR,therebyaffectingnuclearlevelsofNFκB(phospho-p65).ERKinhibitionorsiRNA-mediateddown-regulationofRAF1suppressedthepost-irradiationsurvivaloftheexaminedlungcancercelllines.AsimilareffectwasdetectedonsurvivaluponsilencingIKKα/IKKγorinhibitingIKKβ.Conclusions:ExposureoflungcancercellstoIRresultsinNFκBactivationviaIKK.ThegeneticorpharmacologicalblockageoftheRAF1-ERK-IKK-NFκBpathwaysensitizescellstotherapeuticdosesofradiation.Therefore,theIKKpathwayisapromisingtargetfortherapeuticinterventionincombinationwithradiotherapy.
简介:Objective:TodeterminewhetherInterferon-alpha-2b(IFN-α2b)canmodulatetheautophagicresponseinhepatocellularcarcinomacells.Methods:HepatocellularcarcinomacellsweretreatedwithIFN-α2b.Autophagywasassessedbyacridineorangestaining,GFP-LC3dottedassay,transmissionelectronmicroscopyandimmunoblotting.Results:AcridineorangestainingshowedthatIFN-α2btriggeredtheaccumulationofacidicvesicularandautolysosomesinHepG2cells.TheacridineorangeHepG2cellratioswere(4.3±1.0)%,(6.9±1.4)%,and(13.1±2.3)%,respectively,aftertreatmentwith100,1,000,and10,000IU/mLIFN-α2bfor48h.AmarkedlypunctatepatternwasobservedinHepG2cellstreatedwith10,000IU/mLIFN-α2bfor48h,butonlydiffuseandweaklyfluorescentGFP-LC3punctawasobservedincontrolcells.HepG2cellstreatedwith10,000IU/mLIFN-α2bfor48hdevelopedautophagosome-likecharacteristics,includingsingle-ordouble-membranevacuolescontainingintactanddegradedcellulardebris.TheBeclin1andLC3-IIproteinexpressionwasup-regulatedbyIFN-α2btreatment.Conclusion:Autophagycanbeinducedinadose-dependentmannerbytreatmentwithIFN-α2binHepG2cells,andtheBeclin1signalingpathwaywasstimulatedbyIFN-α2b.
简介:Objective:Toinvestigatephospho-(-cateninexpressioninnon-smallcelllungcancer(NSCLC)andtostudytherelationshipbetweenphospho-(-cateninexpressionandsomeclinicalpathologicalfactors.Methods:Theexpressionofphospho-(-cateninin67primaryNSCLCcasesdetectedimmunohistochemically.Results:phospho-(-cateninwasnotexpressedinnormalbronchialmucouscellandshowedcytoplasmicandnuclearexpressioninNSCLCcell.Totalpositiveexpressionratereached62.7%,andpositiveexpressionrateofnucleuswas38.8%.Thepositiveexpressionrate(87.5%)andnuclearexpressionrateofadenocarcinoma(62.5%)wereapparentlyhigherthanthoseofsquamouscellcancer(40.0%and17.1%)(P<0.01).Expressionofphospho-(-cateninhadnorelationshiptodifferentiationdegreeandlymphaticmetastasis.Thepostoperativesurvivaltimeisnotrelatedtophospho-(-cateninexpression.(Log-ranktest,P=0.9198;P=0.6274).COXmodelanalysisshowedthattumorstageanddifferentiationareindependentriskfactorstoprognosis(P=0.001;P=0.020).Conclusion:NSCLCcellsshowpositiveexpressionofphospho-(-catenin,phospho-(-cateninnuclearexpressionisrelevanttohistologicaltypes.Thereisnodifferenceinpostoperativesurvivaltimebetweenpatientswithphospho-(-cateninpositiveexpressionandpatientswithnegativeexpression,expressionofphospho-(-cateninisnotindependentriskfactortoprognosis.
简介:Objective:Toassesstheclinicalfeatures,survivalandprognosticfactorsofprimarytesticulardiffuselargeB-celllymphoma(DLBCL).Methods:Aretrospectivestudyof37patientswithprimarytesticularDLBCLwascarriedoutfromNovember2003toMay2012.Theirclinicalfeatures,survivalandprognosticfactorswereanalyzed.Results:Duringamedianfollow-upperiodof39.8months(5.4-93.0months),themedianprogression-freesurvival(PFS)was26.2months(95%CI:0-65months)andthe3-yearoverallsurvival(OS)ratewas78.4%.Withinthewholecohort,thefactorssignificantlyassociatedwithasuperiorPFSwerelimitedstage(stageI/II),lactatedehydrogenase(LDH)≤245U/L,internationalprognosticindex(IPI)≤1,primarytumordiameter<7.5cm,andpatientswhohadcompleteresponse(CR)andreceiveddoxorubicin-containedchemotherapy(P<0.05).Therewasatrendtowardsuperioroutcomeforpatientswhoreceivedcombinedtherapy(surgery/chemotherapy/radiotherapy)(P=0.055).PatientswhohadCR,primarytumordiameter<7.5cmandIPIscore≤1weresignificantlyassociatedwithlongerPFSatmultivariateanalysis.Conclusions:PrimarytesticularDLBCLhadpoorersurvival.CR,primarytumordiameterandIPIwereindependentprognosticfactors.Thecombinedtherapyoforchectomy,doxorubicin-containedchemotherapyandcontralateraltesticularradiotherapy(RT)seemedtoimprovesurvival.
简介:目的:研究miR-940对胃癌细胞增殖的影响,探讨miR-940和Cbl-b信号转导通路在此过程中的作用。方法:采用Real-timePCR法检测胃癌细胞中miR-940的表达,MTT法检测胃癌细胞的增殖能力,双荧光素酶报告基因检测系统检测miR-940与Cbl-b的结合,Westernblotting实验观察蛋白的表达。结果:MTT法显示miR-940可促进胃癌细胞MGC803的增殖,BLAST对比分析结果显示Cbl-b与miR-940存在结合位点。双荧光素酶报告基因检测系统证实Cbl-b是miR-940的靶基因。Westernblotting结果显示过表达miR-940后,Cbl-b的表达明显下调。Cbl-b抑制胃癌细胞MGC803的增殖。miR-940通过负向调节Cbl-b的表达促进胃癌细胞的增殖。结论:miR-940通过抑制Cbl-b的表达,促进胃癌细胞MGC803的增殖。
简介:目的:研究B7-H4在乳腺癌中的表达情况及其与各临床病理变量之间的相关性。方法:应用免疫组织化学染色分析51例乳腺癌手术患者切除的肿瘤标本的B7-H4的表达情况,分析其与年龄、肿瘤类型、大小、淋巴结转移、肿瘤分期、激素受体表达情况、Her-2/neu状态的相关性。结果:B7-H4可表达于乳腺癌细胞的胞膜上、胞浆内或同时表达于两者之内。88.2%(45/51)的标本B7-H4阳性,并且与肿瘤中Her-2/neu状态(P=0.04)、组织学类型(P=0.002)明显相关,Her-2/neu阳性患者中B7-H4的表达要明显高于阴性的患者,浸润性导管癌细胞中B7-H4的表达显著高于原位癌,而与其他临床病理参数无关。结论:B7-H4可能与肿瘤的预后和肿瘤的进展相关。
简介:目的观察由吉西他滨(GEM)联合顺铂(DDP)、地塞米松(DXM)组成的GDP方案治疗难治性弥漫大B细胞淋巴瘤(DLBCL)的疗效和毒副反应。方法2006年3月至2008年9月收治的25例难治性DLBCL患者,给予吉西他滨1000mg/m^2,第1、8天,静脉滴注;顺铂25mg/m^2,第1—3天,静脉滴注;地塞米松40mg/d,第1—4天,口服。21天为1周期。2个周期后评价疗效,并随访疾病进展情况。结果25例患者中,18例获缓解(72%),其中完全缓解8例(32%),部分缓解10例(40%)。25例患者中位肿瘤进展时间(TTP)为7.5个月(95%CI:7.17~7.82个月)。主要不良反应为骨髓抑制和轻中度的消化道反应。骨髓抑制主要表现为3—4级白细胞减少7例,3级血小板减少5例。结论吉西他滨联合顺铂、地塞米松的GDP方案治疗难治性DLBCL的近期疗效较好,安全性较高。
简介:Objective:TostudythesynergiceffectsofIL-12andB7-1transfectantonantitumorimmunityinvivo.Methods:TheretrovirusvectorencodingmIL-12andmB7-1genewastranfectedintoEL-4thymiclymphomacellsrespectively.Thecellswereusedastumorvaccineandthetherapeuticeffectwasobserved.Results:IncontrasttothemiceimmunizedwithEL-4/WtorEL-4/Neogroups,thetumorigenicityofEL-4/IL-12transfectantwasdecreased(P<0.001).TheEL-4/IL-12andEL-4/B7-1cellsirradiatedwith60CoshowedsignificantsystematicprotectiveeffectsagainsttherechallengeofEL-4/Wt.60CoirradiatedEL-4/IL-12cellsdelayedtheoccurrenceoftumorandprolongedthesurvivalperiodoftumorbearingmice.CombinationofthevaccinesofEL-4/IL-12andEL-4/B7-1resultedintheenhancedtherapeuticeffectcomparedwitheachsingletransfectantgroup(P<0.001).Conclusion:TheresultsshowedthatIL-12transducedcellscouldenhancetheantitumorimmunityofhostascancervaccine.CombinationoftheEL-4/IL-12andEL-4/B7-1transfectantcouldimproveimmunityofhostandisaprospectcancervaccine.
简介:目的:在既往的胃癌蛋白质组研究中我们已发现hnRNPA2/B1具有较高表达,本试验进一步探讨hnRNPA2/B1在胃癌中的表达情况及其与胃癌临床病理特征的关系。方法:用免疫组织化学方法检测122例胃癌患者的胃癌组织及癌旁正常胃粘膜中hnRNPA2/B1蛋白的表达。结果:hnRNPA2/B1在胃癌组织中核表达的阳性率为92.6%(113/122),其中伴有胞浆表达的阳性率为7.3%(9/122)。在癌旁非瘤组织中核表达阳性率为87.7%(107/122),未见胞浆表达。hnRNPA2/B1的表达状态与胃癌临床病理特征无关联。结论:在胃癌及癌旁非瘤组织中均可发现hnRNPA2/B1核表达,hnRNPA2/B1不能作为肿瘤相关的分子标志物。